News
-
Zambon has presented results from its Phase 3 PROMIS-I study of CMS colistimethate sodium powder demonstrating that a CMS solution delivered via the Philips I-neb nebulizer significantly reduced exacerbations in patients with non-cystic fibrosis bronchiectasis… Read more . . .
-
According to Impel NeuroPharma, the FDA has approved the company’s Trudhesa dihydroergotamine mesylate nasal spray for the treatment of migraine. Impel submitted the NDA for Trudhesa (INP104) in November 2020, and the agency accepted the… Read more . . .
-
Nocion Therapeutics has dosed the first 10 subjects in a Phase 2a study of NOC-100, an inhaled formulation of its NTX-1175, a charged sodium channel blocker, the company said. Nocion is developing NTX-1175 for the… Read more . . .
-
ARS Pharmaceuticals said that it has raised $55 million in a Series D financing round to support approval and potential launch of its Neffy (ARS-1) intranasal epinephrine for the treatment of anaphylaxis as well as… Read more . . .
-
The Medicon Valley Inhalation Consortium (MVIC) has announced that the 2021 Medicon Valley Inhalation Symposium (MVIS), which was to take place on October 13-14 in Lund, Sweden, has been postponed indefinitely. The MVIC training session… Read more . . .
-
Within one week in August, Vivera Pharmaceuticals has announced the issuance of two US patents covering its Zicoh smart inhaler technology. The first is US Patent No. 11,083,850 (“Secure smart dosing system with automated delivery,… Read more . . .
-
The FDA has granted orphan drug designation to Aerami Therapeutics’s AER-901 inhaled imatinib for the treatment of pulmonary arterial hypertension (PAH), the company said. Aerami initiated a Phase 1 trial of AER– 901 in June… Read more . . .
-
Lupin Healthcare has announced the launch of the Luforbec beclometasone/formoterol MDI in the UK. The generic version of Chiesi’s Fostair MDI was approved by the MHRA for the treatment of asthma and COPD in June… Read more . . .
-
Particle engineering company Crystec has announced a new partnership with SignalRx Pharmaceuticals for development of an inhaled dry powder formulation of SignalRx’s SF2523 PI3K-BRD4 inhibitor for the treatment of pulmonary fibrosis, lung cancer, and COVID-19.… Read more . . .
-
According to Liquidia Corporation, the FDA has completed a pre-approval inspection of Liquidia’s facility in Morrisville, North Carolina, USA, where the company will manufacture LIQ861 dry powder treprostinil if approved. No Form 483 observations were issued. The… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan